Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

Not available.

[1]  Daniela Cilloni,et al.  Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? , 2019, International journal of molecular sciences.

[2]  Torsten Haferlach,et al.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.

[3]  H. Dombret,et al.  Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[5]  J. Cayuela,et al.  Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[7]  Mikael Kubista,et al.  How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments , 2015, Biomolecular detection and quantification.

[8]  N. Schmitz,et al.  Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia , 2015 .

[9]  J. Cayuela,et al.  Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. , 2013, Blood.

[10]  E. Paietta,et al.  Minimal residual disease in acute myeloid leukemia: coming of age. , 2012, Hematology. American Society of Hematology. Education Program.

[11]  F. Lo‐Coco,et al.  Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Kim,et al.  Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype , 2009, International journal of hematology.

[13]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[14]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[15]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.